CTLA4 and neoplasm: Research has indicated that when immune checkpoint blockers (such as anti-ctLA-4 and/or anti-Pd-1) are used in combination with anticancer vaccines in immunotherapy, it can suppress tumor growth while also increasing the proportion of effector T cells that produce IFN-γ (39).